title: Effect of beta-blockade on regional left ventricular function in patients with dilated cardiomyopathy.
abstract: It has been reported that beta-blockade has beneficial effects on the cardiac function and prognosis of patients with congestive heart failure. However, the mechanism for these effects remained unclear. This study compared the use of an angiotensin-converting enzyme (ACE) inhibitor (enalapril, 2.5 to 5.0 mg/day, or delapril, 15 to 30 mg/day) alone with the effects of beta-blockade therapy (metoprolol, 40 to 60 mg/day) coupled with an ACE inhibitor on global and regional left ventricular (LV) function in patients with dilated cardiomyopathy. In 12 patients with dilated cardiomyopathy, the global LV ejection fraction (EF), regional EF (rEF), and regional ejection time (rET) were determined by sector analysis of the radionuclide ventriculogram before and after therapy (duration 14 +/- 9 months). The coefficients of variation of rEF and rET were calculated as indexes of the heterogeneity of regional LV systolic wall motion. EF increased significantly from 20% +/- 8% to 30% +/- 8% (p < 0.05) in patients who received beta-blockade and an ACE inhibitor (n = 5). Furthermore, the coefficients of variation of rET decreased from 27% +/- 13% to 16% +/- 7% (p < 0.05). In contrast, patients treated with an ACE inhibitor only (n = 7) showed no significant improvements in any of these parameters. These results suggest that, compared with an ACE inhibitor alone, beta-blockade improves global and regional LV function in dilated cardiomyopathy by synchronizing myocardial contraction.
authors.affiliation: First Department of Medicine, Osaka University Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Morozumi
authors.forename: Y
authors.initials: Y
authors.lastname: Ishida
authors.forename: H
authors.initials: H
authors.lastname: Kusuoka
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Hori
authors.forename: T
authors.initials: T
authors.lastname: Kamada
authors.forename: T
authors.initials: T
authors.lastname: Nishimura
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors